A Phase 2 interventional study of EIDD-2801 and Placebo in SARS-CoV 2, sponsored by Ridgeback Biotherapeutics, LP. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-23.
Sponsored by Ridgeback Biotherapeutics, LP · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19.
Phase 2a randomized, placebo-controlled, double-blinded clinical trial of EIDD-2801 (also known as MK 4482) in adult men and women who have tested positive for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection by polymerase chain reaction (PCR) test within 6 days (144 hours) prior to randomization and are hospitalized with a diagnosis of COVID-19. Rapid enrollment and treatment will be initiated such that the first dose of EIDD-2801 or placebo will be administered as soon as possible and within 7 days of onset of symptoms.
Ridgeback Biotherapeutics, LP is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has COVID-19 disease, defined by having one or more of the following new symptoms and signs (within 7 days):
Pregnancy and : In nonclinical developmental and reproductive toxicity studies, developmental toxicity including malformation was observed in fetuses from pregnant animals dosed with EIDD-2801 (MK 4482). Therefore, treatment with EIDD-2801 is in women who are pregnant or nursing and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during the study and for 4 days after completion of EIDD 2801 dosing in female participants and for 4 days after completion of EIDD-2801 dosing in female partners of male participants.
Given the elevated risk of venous thrombotic events in patients hospitalized with COVID 19 (Benson et al 2020; Spratt et al 2020), estrogen-containing contraceptives must not be started to fulfill the contraceptive requirement of this study at any time during participant's hospitalization. If contraceptives are interrupted as standard of care management of COVID-19 patients and resumed at a later time point, such as at hospital discharge, then abstinence must be practiced for the defined period of back-up contraception per the contraceptive product labeling. After this period, contraceptive use must adhere to Appendix 2.
Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EIDD-2801 orally twice daily (BID) for 5 days at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F
Drug: EIDD-2801
Placebo (PBO) orally twice daily (BID) for 5 days matched for size and appearance to active IP
Drug: Placebo
Oral capsule of EIDD-2801
Also known as: molnupiravir, MK-4482
Oral placebo capsule
Also known as: PBO
Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801
Achievement of undetectable (below the limit of detection of the assay) SARS-CoV-2 RNA by day 5 in NP swabs by quantitative Polymerase Chain Reaction (qPCR) in the Efficacy Analysis Set (EAS). The Efficacy Analysis Set consisted of all participants treated with at least on dose of study drug and with at least 1 post baseline assessment of SARS-CoV-2 RNA in NP swabs by qPCR
Time frame: 28 days
Number of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS
Incidence of Serious Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS in the Safety Population, defined as all participants treated with at least one dose of study drug.
Time frame: 28 days
Number of Participants With Any Adverse Events(AEs) as Assessed by DAIDS
Incidence of Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS
Time frame: 28 days
| Milestone | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Started | 4 | 18 | 25 | 24 |
| Completed | 4 | 13 | 22 | 18 |
| Not completed | 0 | 5 | 3 | 6 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Transferred to rehab | 0 | 0 | 0 | 1 |
| Withdrew: Pt. refused ip after 1 dose | 0 | 0 | 0 | 1 |
Achievement of undetectable (below the limit of detection of the assay) SARS-CoV-2 RNA by day 5 in NP swabs by quantitative Polymerase Chain Reaction (qPCR) in the Efficacy Analysis Set (EAS). The Efficacy Analysis Set consisted of all participants treated with at least on dose of study drug and with at least 1 post baseline assessment of SARS-CoV-2 RNA in NP swabs by qPCR
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Number of Participants That Achieve Virologic Clearance After Oral Administration of EIDD-2801 | 0 | 4 | 10 | 7 |
Incidence of Serious Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS in the Safety Population, defined as all participants treated with at least one dose of study drug.
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Any Serious Adverse Events(SAEs) as Assessed by DAIDS | 0 | 0 | 1 | 3 |
Incidence of Adverse Events in subjects receiving EIDD-2801 as assessed by DAIDS
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Any Adverse Events(AEs) as Assessed by DAIDS | 4 | 11 | 12 | 15 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Molnupiravir 200 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Molnupiravir 400 mg | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Molnupiravir 800 mg | 1/25 (4%) | 1/25 (4%) | 8/25 (32%) |
| Placebo | 0/24 (0%) | 3/24 (12.5%) | 12/24 (50%) |
| Event | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| HypotensionVascular disorders | 0/4 | 0/18 | 0/25 | 1/24 |
| Non-cardiac chest painGeneral disorders | 0/4 | 0/18 | 0/25 | 1/24 |
| BradycardiaCardiac disorders | 0/4 | 0/18 | 0/25 | 1/24 |
| DehydrationMetabolism and nutrition disorders | 0/4 | 0/18 | 0/25 | 1/24 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/4 | 0/18 | 1/25 | 0/24 |
| Hypovolemic shockVascular disorders | 0/4 | 0/18 | 1/25 | 0/24 |
| Event | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Blood glucose increasedInvestigations | 2/4 | 1/18 | 1/25 | 2/24 |
| NauseaGastrointestinal disorders | 1/4 | 2/18 | 0/25 | 0/24 |
| Abdominal discomfortGastrointestinal disorders | 1/4 | 0/18 | 0/25 | 0/24 |
| Blood pressure increasedInvestigations | 1/4 | 0/18 | 0/25 | 1/24 |
| Heart rate increasedInvestigations | 1/4 | 0/18 | 0/25 | 0/24 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/4 | 0/18 | 3/25 | 2/24 |
| AstheniaGeneral disorders | 1/4 | 0/18 | 0/25 | 0/24 |
| HyperglycemiaMetabolism and nutrition disorders | 1/4 | 1/18 | 1/25 | 1/24 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 1/18 | 0/25 | 3/24 |
| AgeusiaNervous system disorders | 1/4 | 0/18 | 0/25 | 0/24 |
| Age, Continuous(years) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.3 ± 9.07 | 52.1 ± 16.37 | 53.5 ± 15.42 | 57.1 ± 14.43 | 54.5 ± 14.93 |
| Sex: Female, Male(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 6 | 11 | 11 | 28 |
| Male | 4 | 12 | 14 | 13 | 43 |
| Ethnicity (NIH/OMB)(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 10 | 11 | 8 | 30 |
| Not Hispanic or Latino | 3 | 8 | 14 | 16 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 1 | 3 |
| Black or African American | 2 | 2 | 7 | 4 | 15 |
| White | 1 | 7 | 12 | 14 | 34 |
| Unknown/Not reported | 0 | 1 | 0 | 1 | 2 |
| Other | 1 | 7 | 3 | 4 | 15 |
| More than one race | 0 | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| SARS-CoV-2 RNA by qPCR in NP Swabs(log 10 copies/mL) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 6.45 ± 1.655 | 4.83 ± 1.487 | 4.77 ± 1.442 | 5.07 ± 1.553 | 5.24 ± 0.42 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Feb 2022, 20 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir
Ridgeback Biotherapeutics, LP